News and analysis on diagnostic technologies and applications.
Researchers have already dosed the first patient with TG4050 and expect to give the immunotherapy to up to 30 more patients in the Phase I study.
A data safety monitoring committee said the trial, exploring the first-line activity of bintrafusp against Keytruda in PD-L1-high, advanced NSCLC, wouldn't meet its primary endpoint.
Natera alleges Inivata infringes its US Patent Nos. 10,262,755 and 10,597,709, which cover cancer monitoring and molecular residual disease testing.